Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026
Early Metabolic Risk in Childhood Brain Cancer Survivors With Childhood-Onset Growth Hormone Deficiency.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Casiraghi Alice, Pollé Olivier, Bailly Clément, Briceno Laura Gonzalez, Doz François, Fresneau Brice, Bourdeaut Franck, Abbou Samuel, Dufour Christelle, Bouchoucha Yassine, Grill Jacques, Pinto Graziella, Samara-Boustani Dinane, Thalassinos Caroline, Viaud Magali, Nguyen-Quoc Adrien, Rovani Sibylle, Stoupa Athanasia, Beccaria Kévin, Blauwblomme Thomas, Persani Luca, Bachelot Anne, Courtillot Carine, Touraine Philippe, Polak Michel, Kariyawasam Dulanjalee
Аннотация
OBJECTIVE: Growth hormone deficiency (GHD) is the earliest and most common pituitary-hormone deficiency in childhood brain cancer (CBC) survivors. To evaluate metabolic and endocrine outcomes in survivors of CBC (excluding craniopharyngiomas) who received growth hormone therapy during childhood, following their transition into adulthood.
METHODS: Observational, multicentric study across 1 pediatric endocrinology, 2 pediatric oncology departments, and 1 adult endocrinology department. Ninety-one CBC survivors with childhood-onset GHD, aged ≥18 years in January 2025, with follow-up data available through April 30, 2025, were included. Assessments included lipid profile, HbA1c, bone mineral density (BMD), body mass index, and pituitary hormone status. Subgroup analyses compared patients with suprasellar versus non-suprasellar tumors and those with persistent adulthood GHD with or without continued GH therapy versus transient GHD. Multivariate analyses were performed.
RESULTS: Median age at last evaluation was 21 years (IQR 19-26). At transition, 71/91 patients (78%) remained GHD. Dyslipidemia affected 54/91 (59.4%) individuals, prediabetes 9/91 (10%), and reduced BMD (osteopenia or osteoporosis) 62/90 (68.6%). Body mass index and HbA1C were significantly higher in the suprasellar subgroup than the non-suprasellar subgroup. Dyslipidemia was not associated with tumor location. No significant differences among patients with persistent GHD on GH therapy, persistent GHD without therapy, or transient GHD.
CONCLUSIONS: Among CBC survivors with childhood-onset GHD, dyslipidemia, impaired glucose metabolism, and reduced BMD are highly prevalent in very early adulthood. Suprasellar tumors show a distinct metabolic vulnerability.
METHODS: Observational, multicentric study across 1 pediatric endocrinology, 2 pediatric oncology departments, and 1 adult endocrinology department. Ninety-one CBC survivors with childhood-onset GHD, aged ≥18 years in January 2025, with follow-up data available through April 30, 2025, were included. Assessments included lipid profile, HbA1c, bone mineral density (BMD), body mass index, and pituitary hormone status. Subgroup analyses compared patients with suprasellar versus non-suprasellar tumors and those with persistent adulthood GHD with or without continued GH therapy versus transient GHD. Multivariate analyses were performed.
RESULTS: Median age at last evaluation was 21 years (IQR 19-26). At transition, 71/91 patients (78%) remained GHD. Dyslipidemia affected 54/91 (59.4%) individuals, prediabetes 9/91 (10%), and reduced BMD (osteopenia or osteoporosis) 62/90 (68.6%). Body mass index and HbA1C were significantly higher in the suprasellar subgroup than the non-suprasellar subgroup. Dyslipidemia was not associated with tumor location. No significant differences among patients with persistent GHD on GH therapy, persistent GHD without therapy, or transient GHD.
CONCLUSIONS: Among CBC survivors with childhood-onset GHD, dyslipidemia, impaired glucose metabolism, and reduced BMD are highly prevalent in very early adulthood. Suprasellar tumors show a distinct metabolic vulnerability.